Evidence map›Paper›PMID 42322078›Full record

ArticleAmerican journal of hematology2026

Long-Term Outcomes of Mayo Stage IIIb AL Amyloidosis Treated With Daratumumab-Based Frontline Therapy.

Simon Zhen, Sorina Nicoleta Bandelita, Divaya Bhutani, Mathew S Maurer, Karan Wats, Yevgeniy Brailovsky, Michael Sang Hughes, Jai Radhakrishnan, Daniel Coriu, Markus Mapara and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Simon ZhenDepartment of Medicine, Columbia University Irving Medical Center, New York, New York, USA.ORCID https://orcid.org/0009-0000-9142-7242
Sorina Nicoleta BandelitaHaematology Department, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania.
Divaya BhutaniDivision of Hematology/Oncology, Columbia University Irving Medical Center, New York, New York, USA.ORCID https://orcid.org/0000-0002-5482-7543
Mathew S MaurerDivision of Cardiology, Columbia University Irving Medical Center, New York, New York, USA.
Karan WatsDivision of Cardiology, Columbia University Irving Medical Center, New York, New York, USA.
Yevgeniy BrailovskyDivision of Cardiology, Columbia University Irving Medical Center, New York, New York, USA.
Michael Sang HughesDivision of Hematology/Oncology, Columbia University Irving Medical Center, New York, New York, USA.
Jai RadhakrishnanDivision of Nephrology, Columbia University Irving Medical Center, New York, New York, USA.
Daniel CoriuHaematology Department, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania.
Markus MaparaDivision of Hematology/Oncology, Columbia University Irving Medical Center, New York, New York, USA.
Suzanne LentzschDivision of Hematology/Oncology, Columbia University Irving Medical Center, New York, New York, USA.
Rajshekhar ChakrabortyDivision of Hematology/Oncology, Columbia University Irving Medical Center, New York, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

of baseline characteristics, treatment regimens, hematologic and cardiac responses, and survival outcomes among 51 patients with Mayo stage IIIb AL amyloidosis treated with daratumumab-based frontline therapy.

Indexed as

AmyloidosisAntibodies, MonoclonalAdultAgedAged, 80 and overFemaleHumansIntention to Treat AnalysisMaleMiddle AgedSurvival RateTime FactorsTreatment OutcomeAntibodies, Monoclonaldaratumumab

Identifiers

PMID42322078
PMCPMC13428388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.